Improving hepatitis C direct-acting antiviral access and uptake

A role for patient-reported outcomes and lived experience

Stelliana Goutzamanis, Joseph Doyle, Peter Higgs, Margaret Hellard

Research output: Contribution to journalArticleOtherpeer-review

2 Citations (Scopus)

Abstract

Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, particularly for “hard-to-reach” populations. Treatment advances and cure will also likely alter the individual experience of living with hepatitis C. However, it is not yet known in what capacity. This paper provides an overview of the population-level impact of DAA treatment, highlighting the need to further our understanding of the impact of treatment on behaviour, health and wellbeing through lived experience and more sensitive patient-reported outcome measures.

Original languageEnglish
Pages (from-to)218-223
Number of pages6
JournalJournal of Viral Hepatitis
Volume26
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Cite this

@article{003ef478c4c64ed29fe3c9e80b94e7f1,
title = "Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience",
abstract = "Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, particularly for “hard-to-reach” populations. Treatment advances and cure will also likely alter the individual experience of living with hepatitis C. However, it is not yet known in what capacity. This paper provides an overview of the population-level impact of DAA treatment, highlighting the need to further our understanding of the impact of treatment on behaviour, health and wellbeing through lived experience and more sensitive patient-reported outcome measures.",
author = "Stelliana Goutzamanis and Joseph Doyle and Peter Higgs and Margaret Hellard",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/jvh.13020",
language = "English",
volume = "26",
pages = "218--223",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "2",

}

Improving hepatitis C direct-acting antiviral access and uptake : A role for patient-reported outcomes and lived experience. / Goutzamanis, Stelliana; Doyle, Joseph; Higgs, Peter; Hellard, Margaret.

In: Journal of Viral Hepatitis, Vol. 26, No. 2, 01.02.2019, p. 218-223.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Improving hepatitis C direct-acting antiviral access and uptake

T2 - A role for patient-reported outcomes and lived experience

AU - Goutzamanis, Stelliana

AU - Doyle, Joseph

AU - Higgs, Peter

AU - Hellard, Margaret

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, particularly for “hard-to-reach” populations. Treatment advances and cure will also likely alter the individual experience of living with hepatitis C. However, it is not yet known in what capacity. This paper provides an overview of the population-level impact of DAA treatment, highlighting the need to further our understanding of the impact of treatment on behaviour, health and wellbeing through lived experience and more sensitive patient-reported outcome measures.

AB - Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, particularly for “hard-to-reach” populations. Treatment advances and cure will also likely alter the individual experience of living with hepatitis C. However, it is not yet known in what capacity. This paper provides an overview of the population-level impact of DAA treatment, highlighting the need to further our understanding of the impact of treatment on behaviour, health and wellbeing through lived experience and more sensitive patient-reported outcome measures.

UR - http://www.scopus.com/inward/record.url?scp=85056123980&partnerID=8YFLogxK

U2 - 10.1111/jvh.13020

DO - 10.1111/jvh.13020

M3 - Article

VL - 26

SP - 218

EP - 223

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 2

ER -